Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 7/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30815824 | 1.00 | KDM1A (0.48) | KDM1AACVR1DPP4ACACBCHRM4 | |
| SCHEMBL377873 | 0.88 | ACVR1 (0.45) | KDM1AACVR1DPP4SUV39H2 | |
| SCHEMBL21397270 | 0.84 | CHRM4 (0.49) | KDM1ADPP4ACACBCHRM4SUV39H2 | |
| SCHEMBL17241036 | 0.81 | ALDH1A1 (0.54) | — | |
| SCHEMBL1704676 | 0.80 | MEN1 (0.43) | KDM1AACACB | |
| Hydrochloric Acid SCHEMBL17870558 | 0.80 | ALDH1A1 (0.45) | KDM1AACACBCHRM4FFAR1 | |
| SCHEMBL517608 | 0.80 | GAK (0.49) | DPP4SUV39H2 | |
| SCHEMBL1911855 | 0.80 | DPP4 (0.53) | ACVR1DPP4SUV39H2 | |
| SCHEMBL14922721 | 0.80 | SIRT6 (0.55) | ACVR1 | |
| SCHEMBL2766132 | 0.78 | ADRB1 (0.56) | ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574176-B | Heteroaryl compound and application thereof | 隆泰申医药科技(南京) 有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2021057696-A1 | HETEROARYL COMPOUND AND APPLICATION THEREOF | 隆泰申医药科技(南京)有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574176-A | Heteroaryl compound and application thereof | 隆泰申医药科技(南京) 有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-8012981-B2 | Benzylpiperazine derivatives as motilin receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | KDM1A 3787/4885ACVR1 1168/4885DPP4 647/4885 |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | KDM1A 3787/4885ACVR1 1168/4885DPP4 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.